Literature DB >> 4027141

pH lability in serum during equilibrium dialysis.

O Brørs, S Jacobsen.   

Abstract

Changes in pH were determined in previously frozen normal human serum during dialysis against sodium phosphate, Krebs Ringer phosphate or Krebs Ringer bicarbonate buffers of pH 7.4. Serum was either untreated (native) or adjusted to pH 7.4 before dialysis. pH in native serum was 7.7-7.9 before dialysis, showed a decrease after 1 h, and an increase after 3 h. pH-adjusted serum showed a continuous pH increase during dialysis. The increase in serum pH during dialysis was larger at 37 degrees C than at 22 degrees C, larger at low than at high buffer molarity, and larger in native than in pH-adjusted serum. The observed changes in serum pH during dialysis are associated with unacceptably large errors in unbound fraction in serum for a number of important drugs. Drug binding determination in serum by equilibrium dialysis should be performed with buffers providing appropriate and stable pH level.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4027141      PMCID: PMC1400630          DOI: 10.1111/j.1365-2125.1985.tb02803.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  The interaction of barbiturates with serum albumin and its possible relation to their disposition and pharmacological actions.

Authors:  L R GOLDBAUM; P K SMITH
Journal:  J Pharmacol Exp Ther       Date:  1954-06       Impact factor: 4.030

2.  Effect of pH on the binding of theophylline to serum proteins.

Authors:  J J Vallner; W A Speir; R C Kolbeck; G N Harrison; E D Bransome
Journal:  Am Rev Respir Dis       Date:  1979-07

3.  A model for the pH dependence of drug-protein binding.

Authors:  J A Henry; A W Dunlop; S N Mitchell; P Turner; P Adams
Journal:  J Pharm Pharmacol       Date:  1981-03       Impact factor: 3.765

4.  Binding of theophylline in human serum determined by ultrafiltration and equilibrium dialysis.

Authors:  O Brørs; G Sager; D Sandnes; S Jacobsen
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

5.  Equilibrium dialysis for determination of protein binding or imipramine--evaluation of a method.

Authors:  C B Kristensen; L F Gram
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1982-02

6.  Factors influencing theophylline serum protein binding.

Authors:  L M Shaw; L Fields; R Mayock
Journal:  Clin Pharmacol Ther       Date:  1982-10       Impact factor: 6.875

7.  Pethidine binding in plasma: effects of methodological variables.

Authors:  C La Rosa; L E Mather; D J Morgan
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

8.  The effect of albumin conformation on the binding of warfarin to human serum albumin. The dependence of the binding of warfarin to human serum albumin on the hydrogen, calcium, and chloride ion concentrations as studied by circular dichroism, fluorescence, and equilibrium dialysis.

Authors:  J Wilting; W F van der Giesen; L H Janssen; M M Weideman; M Otagiri; J H Perrin
Journal:  J Biol Chem       Date:  1980-04-10       Impact factor: 5.157

  8 in total
  4 in total

1.  A comparison of drug protein binding and alpha 1-acid glycoprotein concentration in Chinese and Caucasians.

Authors:  J Feely; T Grimm
Journal:  Br J Clin Pharmacol       Date:  1991-05       Impact factor: 4.335

2.  Differences in the serum binding determinants of isradipine and darodipine--consequences for serum protein binding in various diseases.

Authors:  J L Pinquier; S Urien; P Chaumet-Riffaud; J P Tillement
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

3.  Interethnic differences in drug protein binding and alpha 1 acid glycoprotein concentration.

Authors:  S J Hosseine; R Farid; M R Ghalighi; J Feely
Journal:  Ir J Med Sci       Date:  1995-01       Impact factor: 1.568

Review 4.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.